• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗溶组织内阿米巴引起的腹泻的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。

Evaluation of new anti-infective drugs for the treatment of diarrhea caused by Entamoeba histolytica. Infectious Diseases Society of America and the Food and Drug Administration.

作者信息

Cooperstock M, DuPont H L, Corrado M L, Fekety R, Murray D M

机构信息

Department of Pediatrics, University of Missouri Medical School, Columbia.

出版信息

Clin Infect Dis. 1992 Nov;15 Suppl 1:S254-8. doi: 10.1093/clind/15.supplement_1.s254.

DOI:10.1093/clind/15.supplement_1.s254
PMID:1477239
Abstract

Entamoeba histolytica causes colonic infection that ranges from asymptomatic carriage to invasive disease with infection of extraintestinal organs, particularly the liver. The disease occurs in both sporadic and epidemic forms. Diagnosis requires visualization of trophozoites or cysts by microscopic examination of stool, colonic scrapings, or biopsy specimens. Patients with either asymptomatic or symptomatic disease may be eligible for clinical trials. A prospective, randomized, double-blind, placebo-controlled study design is recommended for asymptomatic carriers and an active-concurrent-control study design for symptomatic patients. Final outcome should be assessed 48 hours to 7 days after completion of therapy. Assessment of microbiological outcome is paramount.

摘要

溶组织内阿米巴可引起结肠感染,其感染程度从无症状携带到伴有肠外器官(尤其是肝脏)感染的侵袭性疾病不等。该疾病以散发和流行两种形式出现。诊断需要通过对粪便、结肠刮片或活检标本进行显微镜检查来观察滋养体或包囊。无症状或有症状疾病的患者都可能符合临床试验条件。对于无症状携带者,建议采用前瞻性、随机、双盲、安慰剂对照的研究设计;对于有症状的患者,则采用活性同期对照研究设计。治疗结束后48小时至7天应评估最终结果。微生物学结果的评估至关重要。

相似文献

1
Evaluation of new anti-infective drugs for the treatment of diarrhea caused by Entamoeba histolytica. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗溶组织内阿米巴引起的腹泻的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S254-8. doi: 10.1093/clind/15.supplement_1.s254.
2
Evaluation of new anti-infective drugs for the treatment of diarrhea caused by Cryptosporidium. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗隐孢子虫引起的腹泻的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S249-53. doi: 10.1093/clind/15.supplement_1.s249.
3
Evaluation of new anti-infective drugs for the treatment of diarrhea caused by Giardia lamblia. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗蓝氏贾第鞭毛虫引起的腹泻的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S244-8. doi: 10.1093/clind/15.supplement_1.s244.
4
Evaluation of new anti-infective drugs for the treatment of cholera. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗霍乱的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S241-3. doi: 10.1093/clind/15.supplement_1.s241.
5
Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗急性感染性腹泻的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S228-35. doi: 10.1093/clind/15.supplement_1.s228.
6
Evaluation of new anti-infective drugs for the treatment of disease caused by Mycobacterium kansasii and other mycobacteria. Infectious Diseases Society of America and the Food and Drug Administration.新型抗感染药物治疗堪萨斯分枝杆菌及其他分枝杆菌所致疾病的评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S307-12. doi: 10.1093/clind/15.supplement_1.s307.
7
Evaluation of new anti-infective drugs for the treatment of chronic carriage of Salmonella. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗沙门氏菌慢性携带的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S259-62. doi: 10.1093/clind/15.supplement_1.s259.
8
Evaluation of new anti-infective drugs for the treatment of viral encephalitis. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗病毒性脑炎的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S195-9. doi: 10.1093/clind/15.supplement_1.s195.
9
Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Infectious Diseases Society of America and the Food and Drug Administration.新型抗真菌药物治疗隐球菌性脑膜炎的评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S189-94. doi: 10.1093/clind/15.supplement_1.s189.
10
Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗中性粒细胞减少患者发热性发作的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S206-15. doi: 10.1093/clind/15.supplement_1.s206.

引用本文的文献

1
Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis.塞克硝唑。对其抗菌活性、药代动力学特性以及在原生动物感染和细菌性阴道病治疗中的应用综述。
Drugs. 1996 Apr;51(4):621-38. doi: 10.2165/00003495-199651040-00007.